Insight Molecular Diagnostics Inc. (IMDX)vsIQVIA Holdings Inc (IQV)
IMDX
Insight Molecular Diagnostics Inc.
$4.14
+3.50%
HEALTHCARE · Cap: $122.19M
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 370413% more annual revenue ($16.31B vs $4.40M). IQV leads profitability with a 8.3% profit margin vs 0.0%. IQV earns a higher WallStSmart Score of 72/100 (B).
IMDX
Avoid27
out of 100
Grade: F
IQV
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMDX.
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 126.1% year-over-year
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -236.0% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IMDX
The strongest argument for IMDX centers on Revenue Growth. Revenue growth of 126.1% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : IMDX
The primary concerns for IMDX are EPS Growth, Market Cap, Profit Margin.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Key Dynamics to Monitor
IMDX profiles as a hypergrowth stock while IQV is a value play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.41 — expect wider price swings.
IMDX is growing revenue faster at 126.1% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 27/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insight Molecular Diagnostics Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?